May 7, 2026 — A landmark collaboration between Halozyme Therapeutics and Oruka Therapeutics could reshape the future of psoriasis treatment. The two biotech companies have announced a global exclusive license agreement to develop ORKA-001—a promising biologic targeting interleukin-23 (IL-23p19)—using Halozyme’s proprietary Hypercon™ technology. This innovation aims to dramatically reduce injection volumes for biologics, potentially making life-changing therapies more convenient for millions of patients with chronic inflammatory skin diseases.

The agreement, announced on May 6, 2026, marks Halozyme’s second Hypercon collaboration this year, signaling growing industry confidence in the technology’s ability to improve drug delivery. For Oruka, the partnership represents a strategic leap forward in its mission to develop transformative treatments for psoriasis and related conditions. But what exactly is Hypercon™ and why could this collaboration be a game-changer for patients worldwide?

Key Takeaways:

• Exclusive License: Oruka gains global rights to use Hypercon™ for ORKA-001 (targeting IL-23p19) and one additional therapeutic target.
• Technology Breakthrough: Hypercon™ enables hyperconcentration of biologics, reducing injection volumes by up to 90% while maintaining full potency.
• Patient Impact: Smaller, more convenient injections could improve adherence and quality of life for psoriasis sufferers.
• Financial Terms: Halozyme stands to receive upfront payments, milestone fees, and mid-single-digit royalties on net sales.
• Regulatory Pathway: Both companies are pursuing accelerated development timelines for ORKA-001.

Halozyme and Oruka’s Psoriasis Breakthrough: How Hypercon™ Could Redefine Biologic Therapy

Psoriasis affects over 125 million people globally, yet current biologics—while effective—often come with significant drawbacks. Many require large injection volumes, frequent dosing, and administration by healthcare professionals, creating barriers to treatment adherence. Enter Hypercon™, Halozyme’s microparticle technology designed to overcome these challenges by enabling the hyperconcentration of therapeutic proteins.

Under the new agreement, Oruka will integrate Hypercon™ into its lead candidate, ORKA-001, an investigational biologic targeting the p19 subunit of interleukin-23 (IL-23). IL-23 is a key driver of inflammation in psoriasis, and blocking its activity has shown remarkable efficacy in clinical trials. However, traditional biologics targeting IL-23 often require weekly or biweekly injections of 1–2 mL—volumes that can deter patients, particularly those managing chronic conditions at home.

“We are pleased to announce our second Hypercon collaboration this year, further validating the broad applicability and partner interest in this technology,” said Dr. Helen Torley, President and CEO of Halozyme, in a statement released on May 6, 2026. “We look forward to advancing Hypercon with Oruka’s innovative biologics that are designed to deliver meaningful freedom from chronic disease for patients.”

“We are excited to partner with Halozyme’s Hypercon in our pursuit to offer the best possible medicines to people with chronic skin conditions like psoriasis. We look forward to applying the full potential of this technology to our product candidates to further enhance the profile we can deliver to patients over time.”

What Is Hypercon™ and How Does It Work?

Hypercon™ is a proprietary microparticle delivery system that allows for the hyperconcentration of biologics and small molecules. By encapsulating drugs within tiny, biodegradable particles, the technology enables doses that would normally require 1–2 mL of injection fluid to be delivered in as little as 0.05–0.1 mL—a 90% reduction in volume—without compromising efficacy.

Beyond smaller injection volumes, Hypercon™ offers several potential advantages:

• Improved Patient Compliance: Fewer injections and reduced pain may encourage patients to adhere to treatment regimens.
• Self-Administration: Smaller volumes make it easier for patients to administer treatments at home.
• Reduced Burden on Healthcare Providers: Clinics may see fewer visits for injections, freeing up resources.
• Potential for Less Frequent Dosing: Early data suggests hyperconcentration may enable extended dosing intervals.

The technology has already shown promise in preclinical and early clinical studies. In a 2025 Phase 1b trial, Hypercon™-enabled adalimumab (a TNF inhibitor) demonstrated comparable safety and efficacy to the standard formulation but with a 90% smaller injection volume. If similar results are seen with ORKA-001, the impact on psoriasis treatment could be profound.

Psoriasis Treatment Landscape: Why This Collaboration Matters

Psoriasis is not just a skin disease—it’s a systemic inflammatory condition linked to increased risks of cardiovascular disease, diabetes, and depression. Despite the availability of biologics like secukinumab (Cosentyx), ustekinumab (Stelara), and guselkumab (Tremfya), many patients struggle with treatment limitations:

• Injection Fatigue: Frequent, large-volume injections lead to non-adherence in up to 30–40% of patients.
• Access Barriers: Some biologics require refrigeration or specialized administration.
• Cost: Annual treatment costs can exceed $50,000 per patient, creating financial strain.

ORKA-001 represents a new approach by targeting IL-23p19 specifically, rather than the broader IL-23/IL-12 complex targeted by existing therapies. Early preclinical data suggest it may offer a superior safety profile with potential for fewer side effects like infections or malignancies—a common concern with long-term IL-23 inhibition.

The addition of Hypercon™ could further differentiate ORKA-001 in a crowded market. Competitors like AbbVie’s deglizumab and Janssen’s risankizumab (Skyrizi) have also explored IL-23 pathways, but none have yet integrated advanced delivery technologies like Hypercon™.

Behind the Deal: Financial Terms and Strategic Goals

The collaboration includes several key financial components, though exact figures remain undisclosed:

• Upfront Payment: Halozyme will receive an undisclosed upfront payment from Oruka upon signing the agreement.
• Milestone Payments: Additional payments are tied to developmental milestones, including preclinical success, clinical trial readouts, and regulatory approvals.
• Royalties: Halozyme is eligible for mid-single-digit royalties on net sales of products utilizing Hypercon™ technology.
• Option for Additional Targets: The agreement includes an option for Oruka to license Hypercon™ for up to one additional therapeutic target beyond ORKA-001.

For Halozyme, the deal reinforces its strategy of licensing Hypercon™ to partners across therapeutic areas. The company’s first Hypercon collaboration in 2026 involved an undisclosed partner in the oncology space, suggesting broad interest in the technology’s versatility. “This agreement underscores the growing recognition of Hypercon™ as a platform technology that can enhance the delivery of biologics across multiple disease areas,” said Torley.

Oruka, meanwhile, is betting on Hypercon™ to accelerate the development of ORKA-001. The company has stated that integrating the technology could enable less frequent dosing and improve patient convenience—key differentiators in a market where adherence remains a critical challenge.

What This Means for Patients: Smaller Injections, Bigger Hope

For the millions of people living with psoriasis, the promise of Hypercon™-enabled treatments is clear: smaller, less painful injections. But how soon could patients see these benefits?

ORKA-001 is currently in Phase 1 clinical trials, with Phase 2 studies expected to begin in late 2026 or early 2027. If the trials proceed smoothly, the first Hypercon™-enabled biologics for psoriasis could reach patients as early as 2029–2030, though regulatory timelines can vary.

Patients already using biologics for psoriasis may wonder how this technology could impact them. While ORKA-001 is not yet approved, the collaboration highlights a broader trend: biologics are evolving beyond efficacy to focus on convenience and quality of life. Future treatments may combine advanced molecular targets with smart delivery systems, making therapy more accessible.

Key Questions for Patients:

• Could Hypercon™ reduce the size of my current biologic injections? (Not directly—this applies to future treatments like ORKA-001.)
• Will insurance cover Hypercon™-enabled drugs? Likely, if they demonstrate comparable efficacy with improved convenience.
• How do I stay informed about clinical trials? Register on platforms like ClinicalTrials.gov or contact Oruka Therapeutics directly.

Expert Insight: “A Turning Point for Biologic Delivery”

Dr. Anna Weber, a dermatologist and psoriasis researcher at Charité – Universitätsmedizin Berlin, calls the collaboration “a turning point for how we think about biologic delivery.”

“Psoriasis patients often cite injection burden as a major barrier to treatment. If Hypercon™ can deliver the same therapeutic effect in a fraction of the volume, we could see a significant improvement in adherence. This isn’t just about convenience—it’s about giving patients back control over their lives.”

Dr. Weber notes that while efficacy remains the top priority, “the next frontier in dermatology is making treatments so patient-friendly that they become almost invisible in daily life.” She cautions, however, that real-world data will be crucial: “We’ll need to see long-term safety and efficacy data to ensure that hyperconcentration doesn’t compromise the drug’s performance.”

Next Steps: Development and Regulatory Pathway

The road ahead for ORKA-001 and Hypercon™ includes several critical milestones:

1. Phase 1 Completion (2026): Safety and tolerability data from current trials will determine whether Phase 2 can proceed.
2. Phase 2 Initiation (Late 2026–Early 2027): Dose-ranging studies to evaluate efficacy and optimal dosing intervals.
3. Phase 3 (2028–2029): Large-scale trials comparing ORKA-001 with existing IL-23 inhibitors.
4. Regulatory Submissions (2029–2030): Filings with the FDA and EMA for approval.
5. Market Launch (2030+): Potential commercialization, pending regulatory green lights.

Both companies have indicated they will pursue accelerated approval pathways where possible, which could shorten timelines for patients with unmet needs. Halozyme has also hinted at exploring combination therapies with Hypercon™ in the future.

Beyond Psoriasis: The Future of Hypercon™

While ORKA-001 is the first Hypercon™-enabled biologic for psoriasis, the technology has broader applications. Halozyme has previously explored its use in:

• Oncology: Reducing injection volumes for chemotherapy adjuncts.
• Rheumatology: Potential applications for autoimmune disease treatments.
• Neurology: Exploratory work in protein replacement therapies.

If successful, Hypercon™ could become a standard platform for biologic delivery, much like its patented status suggests. Analysts at BioWorld have described the technology as “a potential disruptor in the $200+ billion biologics market,” given its ability to enhance existing drugs without altering their core mechanisms.